• Citer

CDK4/6 inhibitors in the treatment of patients with breast cancer: Summary of a multidisciplinary round-table discussion

par Preusser, Matthias;de Mattos-Arruda, Letícia;Thill, Marc;Criscitiello, Carmen ;Bartsch, Rupert;Ruhstaller, Thomas;de Azambuja, Evandro ;Zielinski, Christoph
Référence ESMO Open, 3, 5, e000368
Publication Publié, 2018-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

This article is the result of a round-table discussion organised by ESMO Open in Vienna in December 2017. Its purpose is to discuss the background and advances in the evidence regarding cyclin-dependent kinase 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) in the treatment of metastatic and early-stage breast cancer and to explore what the key open research questions are and next steps should be.